ID

37308

Descripción

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1); ODM derived from: https://clinicaltrials.gov/show/NCT02227862

Link

https://clinicaltrials.gov/show/NCT02227862

Palabras clave

Versiones (1)
  1. 15/7/19 15/7/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

15 de julio de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 1 Diabetes NCT02227862

Inglés

Eligibility Type 1 Diabetes NCT02227862

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with an established diagnosis of t1dm per ada 2014 criteria
Descripción

Diabetes Mellitus, Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011854
body mass index (bmi) of 18.5 to 35 kg/m2 at screening (both values inclusive).
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
glycosylated hemoglobin (hba1c) ≤9.5% at screening.
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
hemoglobin ≥9.0 g/dl at screening.
Descripción

Hemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0518015
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, or history of significant allergic drug reactions.
Descripción

Hypersensitivity Insulin Ingredient | Hypersensitivity Insulin Analogue Ingredient | Drug Allergy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0021641
UMLS CUI [1,3]
C1550600
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C2825028
UMLS CUI [2,3]
C1550600
UMLS CUI [3]
C0013182
history of use of animal insulin within the last 3 years or use of biosimilar insulin glargine at any time prior.
Descripción

Animal Insulin | Insulin Glargine Biosimilar

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003062
UMLS CUI [1,2]
C0021641
UMLS CUI [2,1]
C0907402
UMLS CUI [2,2]
C4045974
history of use of a regular immunomodulator therapy in the 1 year prior to screening.
Descripción

Immunomodulatory therapy Regular

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1963758
UMLS CUI [1,2]
C0205272
history of ≥2 episodes of severe hypoglycemia within the 6 months before screening or history of hypoglycemia unawareness (a sample questionnaire is provided in appendix i), as judged by the investigator.
Descripción

Episode Quantity Hypoglycemia Severe | Loss of hypoglycemic warning

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332189
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0020615
UMLS CUI [1,4]
C0205082
UMLS CUI [2]
C0342317
history of ≥1 episodes of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within the 6 months prior to screening.
Descripción

Episode of Diabetic Ketoacidosis | Emergency visit Uncontrolled diabetes mellitus | Hospitalization Due to Uncontrolled diabetes mellitus

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332189
UMLS CUI [1,2]
C0011880
UMLS CUI [2,1]
C0553618
UMLS CUI [2,2]
C0421258
UMLS CUI [3,1]
C0019993
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0421258
serological evidence of human immunodeficiency virus (hiv), hepatitis b (hbsag) or hepatitis c (hcvab) antibodies at screening.
Descripción

HIV Seropositivity | Hepatitis B antibody positive | Hepatitis B surface antigen positive | Hepatitis C antibody positive

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0860013
UMLS CUI [3]
C0149709
UMLS CUI [4]
C0281863
history of drug or alcohol dependence or abuse during the 1 year prior to screening.
Descripción

Substance Dependence | Substance Use Disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038580
UMLS CUI [2]
C0038586
Volver a la parte superior de la página

Similar models

Eligibility Type 1 Diabetes NCT02227862

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent
Item
patients with an established diagnosis of t1dm per ada 2014 criteria
boolean
C0011854 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) of 18.5 to 35 kg/m2 at screening (both values inclusive).
boolean
C1305855 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
glycosylated hemoglobin (hba1c) ≤9.5% at screening.
boolean
C0474680 (UMLS CUI [1])
Hemoglobin measurement
Item
hemoglobin ≥9.0 g/dl at screening.
boolean
C0518015 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Insulin Ingredient | Hypersensitivity Insulin Analogue Ingredient | Drug Allergy
Item
history of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, or history of significant allergic drug reactions.
boolean
C0020517 (UMLS CUI [1,1])
C0021641 (UMLS CUI [1,2])
C1550600 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C2825028 (UMLS CUI [2,2])
C1550600 (UMLS CUI [2,3])
C0013182 (UMLS CUI [3])
Animal Insulin | Insulin Glargine Biosimilar
Item
history of use of animal insulin within the last 3 years or use of biosimilar insulin glargine at any time prior.
boolean
C0003062 (UMLS CUI [1,1])
C0021641 (UMLS CUI [1,2])
C0907402 (UMLS CUI [2,1])
C4045974 (UMLS CUI [2,2])
Immunomodulatory therapy Regular
Item
history of use of a regular immunomodulator therapy in the 1 year prior to screening.
boolean
C1963758 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
Episode Quantity Hypoglycemia Severe | Loss of hypoglycemic warning
Item
history of ≥2 episodes of severe hypoglycemia within the 6 months before screening or history of hypoglycemia unawareness (a sample questionnaire is provided in appendix i), as judged by the investigator.
boolean
C0332189 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0020615 (UMLS CUI [1,3])
C0205082 (UMLS CUI [1,4])
C0342317 (UMLS CUI [2])
Episode of Diabetic Ketoacidosis | Emergency visit Uncontrolled diabetes mellitus | Hospitalization Due to Uncontrolled diabetes mellitus
Item
history of ≥1 episodes of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within the 6 months prior to screening.
boolean
C0332189 (UMLS CUI [1,1])
C0011880 (UMLS CUI [1,2])
C0553618 (UMLS CUI [2,1])
C0421258 (UMLS CUI [2,2])
C0019993 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0421258 (UMLS CUI [3,3])
HIV Seropositivity | Hepatitis B antibody positive | Hepatitis B surface antigen positive | Hepatitis C antibody positive
Item
serological evidence of human immunodeficiency virus (hiv), hepatitis b (hbsag) or hepatitis c (hcvab) antibodies at screening.
boolean
C0019699 (UMLS CUI [1])
C0860013 (UMLS CUI [2])
C0149709 (UMLS CUI [3])
C0281863 (UMLS CUI [4])
Substance Dependence | Substance Use Disorders
Item
history of drug or alcohol dependence or abuse during the 1 year prior to screening.
boolean
C0038580 (UMLS CUI [1])
C0038586 (UMLS CUI [2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial